XOMA Royalty +€2 +7.46% Wednesday 08:59
1D 1W 1M 3M 1Y 5Y
5 Nov Expected
This list is based on the watchlists of people on Stock Events who follow X0M1.F. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap 130.59B
Regeneron Pharmaceuticals competes in the biotechnology industry focusing on developing and commercializing medicines for serious medical conditions, similar to XOMA's focus on antibody-based therapeutics.
Amgen is a biopharmaceutical company that discovers, develops, manufactures, and delivers innovative human therapeutics, competing directly with XOMA in the biotech sector.
Biogen competes with XOMA in the biotechnology field, focusing on developing therapies for neurological and neurodegenerative diseases. Gilead Sciences
GILD
Mkt Cap 98.35B
Gilead Sciences is a biopharmaceutical company that researches, develops, and commercializes drugs in areas similar to XOMA, making them direct competitors. Vertex Pharmaceuticals
VRTX
Mkt Cap 127.99B
Vertex Pharmaceuticals is involved in creating new possibilities in medicine to cure diseases and improve people's lives, competing with XOMA in the biotech innovation space. Alnylam Pharmaceuticals
ALNY
Mkt Cap 33.72B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with XOMA in the development of novel therapeutics.
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, making it a competitor in the biopharmaceutical space alongside XOMA. Nektar Therapeutics
NKTR
Mkt Cap 235.62M
Nektar Therapeutics is involved in developing new treatment options in various therapeutic areas, competing with XOMA in the innovation of biologic drugs. Biomarin Pharmaceutical
BMRN
Mkt Cap 17.36B
BioMarin Pharmaceutical focuses on developing and commercializing innovative biopharmaceuticals for rare diseases, competing with XOMA in targeting niche markets with specialized treatments.
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Show more...
CEO
Mr. Owen P. Hughes Jr.